Inactive Instrument

News Opiant Pharmaceuticals, Inc.

Equities

OPNT

US6837501039

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Indivior completes acquisition of Opiant Pharmaceuticals	23-03-02	AN
Indivior Wraps Up Deal to Buy Opiant Pharmaceuticals	23-03-02	MT
OPIANT PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-03-02	AQ
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from NASDAQ Composite Index	23-03-02	CI
Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from S&P TMI Index	23-03-02	CI
Indivior PLC completed the acquisition of Opiant Pharmaceuticals, Inc. from a group of shareholders.	23-03-01	CI
OPIANT PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23-03-01	AQ
Transcript : Opiant Pharmaceuticals, Inc. - Shareholder/Analyst Call	23-03-01
OPIANT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)	23-02-27	AQ
Indivior Wins US Regulatory Nod To Acquire Opiant Pharmaceuticals	23-02-07	MT
OPIANT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-02-07	AQ
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC	23-02-07	GL
Indivior announces expiry of waiting period for Opiant purchase	23-02-06	AN
Opiant Pharmaceuticals Says Waiting Period Expires for Proposed Takeover by Indivior Expires	23-02-06	MT
Indivior Nears Acquisition of Opiant Pharmaceuticals	23-02-06	MT
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	23-02-06	GL
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC	23-02-06	AQ
Warren tells FTC she is "particularly concerned" about Amgen and Indivior deals	23-01-26	RE
Opiant Pharmaceuticals Granted FDA Priority Review for Opioid Overdose Therapy	23-01-20	MT
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose	23-01-19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Opiant Pharmaceuticals, Inc.

Equities

OPNT

US6837501039

Summary

Filters